Alpha 2.0
Login Register
» Authors » Didier Debieuvre

Didier Debieuvre

Explore the profile of Didier Debieuvre including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 64
Citations 1397
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Virginie Westeel
Franck Morin
Denis Moro-Sibilot
Olivier Molinier
Gerard Zalcman
Elisabeth Quoix
Fabrice Barlesi
Pierre-Jean Souquet
Clarisse Audigier-Valette
Herve Lena
Published In
Lung Cancer
Eur J Cancer
Respir Med Res
Eur Respir J
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Lena H, et al.
Front Oncol . 2025 Mar; 15:1526931. PMID: 40052124
Introduction: This study describes treatment and retreatment patterns and outcomes in patients in France following nivolumab as a second-line or later (2L+) treatment in locally advanced or metastatic non-small cell...
2.
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer
Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, et al.
J Thorac Oncol . 2024 Dec; PMID: 39694415
Objectives: Genomic profiling is a major component for first-line treatment decisions in patients with NSCLC and the timeliness of biomarker testing is essential to improve time to treatment initiation (TTI)...
3.
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, et al.
Lung Cancer . 2024 Dec; 199:108038. PMID: 39616778
Background: BRAF V600E mutations occur in 2-5 % of advanced non-small cell lung cancer (NSCLC) patients. The dabrafenib-trametinib (D-T) combination was associated with improved and durable OS in patients in...
4.
Optimizing Treatment Strategies for -Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights
Thomas Q, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, et al.
Cancers (Basel) . 2024 Nov; 16(21). PMID: 39518004
Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), demonstrated superior efficacy over first-generation TKIs in the FLAURA trial, resulting in its approval as first-line therapy for metastatic non-small-cell lung cancer (NSCLC)....
5.
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting
Falchero L, Meyer N, Molinier O, Al Freijat F, Pegliasco H, Lecuyer E, et al.
Eur J Cancer . 2024 Aug; 210:114277. PMID: 39168000
Background: The KBP studies are real-life nationwide, prospective, multicenter cohort studies of patients diagnosed with primary lung cancer that have been conducted in French non-academic public hospitals each decade since...
6.
Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database
Cabart M, Mourey L, Pasquier D, Schneider S, Lena H, Girard N, et al.
J Geriatr Oncol . 2024 Jul; 15(7):101819. PMID: 39068144
Introduction: In France, 40% of patients diagnosed with lung cancer are ≥70 years old, but these are under-represented in clinical trials. Using data from the French Epidemiological Strategy and Medical...
7.
Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting
Belaroussi Y, Bouteiller F, Bellera C, Pasquier D, Perol M, Debieuvre D, et al.
Sci Rep . 2023 Jun; 13(1):9584. PMID: 37311845
Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in...
8.
Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy
Audigier Valette C, Filleron T, Debieuvre D, Lena H, Perol M, Chouaid C, et al.
Respir Med Res . 2023 Jun; 84:101012. PMID: 37307617
Background: Small cell lung cancer (SCLC) is a highly aggressive entity of lung cancer with tendency toward early recurrence after first-line treatment. As per recently updated European Society for Medical...
9.
ICU admission for solid cancer patients treated with immune checkpoint inhibitors
Toffart A, Meert A, Wallet F, Gibelin A, Guisset O, Gonzalez F, et al.
Ann Intensive Care . 2023 Apr; 13(1):29. PMID: 37072645
Background: Immune checkpoint inhibitors (ICI) have revolutionized the management of cancer. They can induce immune-related adverse events (irAE) leading to intensive care unit (ICU) admission. We aimed to describe irAEs...
10.
Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort
Bringuier M, Carton M, Debieuvre D, Pasquier D, Perol M, Filleron T, et al.
J Geriatr Oncol . 2023 Jan; 14(2):101423. PMID: 36657245
Introduction: There is a great need for data based on clinical trials for the older population in order to improve treatment. Historically, the inclusion rate of older adults in clinical...